Published in

International Union Against Tuberculosis and Lung Disease, International Journal of Tuberculosis and Lung Disease, 2(21), p. 167-174

DOI: 10.5588/ijtld.16.0493

Links

Tools

Export citation

Search in Google Scholar

Examples of Bedaquiline Introduction for the Management of Multidrug-Resistant Tuberculosis in Five Countries

Journal article published in 2017 by L. Guglielmetti ORCID, C. Hewison, Z. Avaliani, J. Hughes, N. Kiria, N. Lomtadze, N. Ndjeka, S. Setkina, A. Shabangu, W. Sikhondze, A. Skrahina, N. Veziris ORCID, J. Furin
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.

Full text: Unavailable

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract available only, full article is not open access. To access this article click on "additional links". ; For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of introduction, however, has not kept pace with patient needs. It is estimated that as many as 23% of multidrug-resistant TB (MDR-TB) patients have an indication for receiving BDQ. As this is the first time the MDR-TB community is introducing new medications, it is important to understand how implementation can be developed in a variety of settings.